Investigating immune responses in patients with low platelet counts
Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)
This study is trying to understand how the immune system works in people with low platelet counts due to immune thrombocytopenia, by looking at certain immune cells in their blood and spleen.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT02821572 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of Fcgamma receptors in patients with immune thrombocytopenia (ITP), an autoimmune condition characterized by low platelet counts. The research will compare the expression of these receptors on circulating monocytes and splenic macrophages in individuals diagnosed with ITP. Blood and spleen samples will be collected from participants to analyze the immune response and its implications in the disease. The study seeks to enhance understanding of the mechanisms underlying ITP and potentially inform future therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with a diagnosis of immune thrombocytopenia and a platelet count of less than 100 G/L.
Not a fit: Patients with autoimmune diseases other than ITP or those under guardianship may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of immune thrombocytopenia, potentially benefiting patients through better-targeted therapies.
How similar studies have performed: While the specific role of Fcgamma receptors in ITP is being explored, similar studies in other autoimmune diseases have shown promising results, suggesting potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: ITP group * Patients who have provided written consent * Patients over 18 years * Patients with national health insurance * Patients with ITP, defined as thrombocytopenia \< 100 G/L, after exclusion of infection- or drug-related thrombocytopenia and malignant hemopathy. Control Group * Persons who have provided a written consent * Persons over 18 years * Persons with national health insurance * Persons without autoimmune disease Exclusion Criteria: * Patients under guardianship * Pregnancy
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Bernard BONNOTTE
- Email: bernard.bonnotte@chu-dijon.fr
- Phone: 3.80.29.34.32
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.